These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 11377521

  • 61. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):635-7. PubMed ID: 7679826
    [No Abstract] [Full Text] [Related]

  • 62. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation.
    Sher LS, Cosenza CA, Petrovic LM, Rojter S, Hoffman A, Lopez RR, Meehan M, Pan SH, Vierling J, Makowka L.
    Transplant Proc; 1996 Apr; 28(2):1011-3. PubMed ID: 8623212
    [No Abstract] [Full Text] [Related]

  • 63. Conversion to tacrolimus after liver transplantation.
    Jonas S, Bechstein WO, Lemmens HP, Kling N, Grauhan O, Lobeck H, Neuhaus P.
    Transpl Int; 1996 Apr; 9(1):23-31. PubMed ID: 8748407
    [Abstract] [Full Text] [Related]

  • 64. Rejection and tacrolimus conversion therapy in paediatric liver transplantation.
    Spada M, Corno V, Colledan M, Segalin A, Lucianetti A, Torre G, Riva S, Sonzogni A, Petz W, Gridelli B.
    Transpl Int; 2000 Apr; 13 Suppl 1():S341-4. PubMed ID: 11112028
    [Abstract] [Full Text] [Related]

  • 65. Long-term results of living kidney transplantation under tacrolimus immunosuppression: a single-center experience.
    Tanabe K, Ishikawa N, Tokumoto T, Takahashi K, Kanematsu A, Kitani R, Fuchinoue S, Oshima T, Yagisawa T, Toma H.
    Transplant Proc; 1998 Jun; 30(4):1224-6. PubMed ID: 9636497
    [No Abstract] [Full Text] [Related]

  • 66. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease.
    Mueller AR, Platz KP, Bechstein WO, Blumhardt G, Lobeck H, Hop U, Neuhaus P.
    Transplant Proc; 1994 Dec; 26(6):3637-9. PubMed ID: 7527984
    [No Abstract] [Full Text] [Related]

  • 67. Influence of immunosuppression on patient outcome after liver transplantation.
    Mueller AR, Platz KP, Willimski C, Berg T, Neuhaus R, Lobeck H, Neuhaus P.
    Transplant Proc; 1998 Jun; 30(4):1495-6. PubMed ID: 9636608
    [No Abstract] [Full Text] [Related]

  • 68. FK 506 used as rescue therapy for refractory liver allograft rejection.
    Chen CL, Eng HL, Chen YS, Kuo YC, Sun CK.
    Transplant Proc; 1994 Aug; 26(4):1927-9. PubMed ID: 7520612
    [No Abstract] [Full Text] [Related]

  • 69. Neoral is superior to FK 506 in liver transplantation.
    Levy GA.
    Transplant Proc; 1998 Aug; 30(5):1812-5. PubMed ID: 9723293
    [No Abstract] [Full Text] [Related]

  • 70. Mycophenolate mofetil for treatment of chronic rejection in liver allograft under tacrolimus.
    Daly I, Jain A, Reyes J, Fung J.
    Transplant Proc; 2002 Aug; 34(5):1503. PubMed ID: 12176458
    [No Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72. Steroid withdrawal 3 months after liver transplantation--does FK 506 confer any advantage over cyclosporin?
    Dmitrewski J, Ayres S, Gunson BK, Buist LJ, Buckels JA, McMaster P, Mayer AD.
    Transpl Int; 1994 Aug; 7 Suppl 1():S85-7. PubMed ID: 11271342
    [Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus).
    Van Buren D, Payne J, Geevarghese S, MacDonell R, Chapman W, Wright JK, Helderman JH, Richie R, Pinson CW.
    Transplant Proc; 1998 Jun; 30(4):1401-2. PubMed ID: 9636566
    [Abstract] [Full Text] [Related]

  • 75. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients.
    Stephens J, Goldstein R, Crippin J, Husberg B, Holman M, Gonwa TA, Klintmalm G.
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1122-3. PubMed ID: 7680144
    [No Abstract] [Full Text] [Related]

  • 76. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil.
    Ringe B, Braun F, Schütz E, Füzesi L, Lorf T, Canelo R, Oellerich M, Ramadori G.
    Transplantation; 2001 Feb 27; 71(4):508-15. PubMed ID: 11258429
    [Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. Efficacy and safety of dual versus triple tacrolimus-based therapy in kidney transplantation: two-year follow-up.
    Garcia I, Spanish-Italian Tacrolimus Study Group.
    Transplant Proc; 2002 Aug 27; 34(5):1638-9. PubMed ID: 12176516
    [No Abstract] [Full Text] [Related]

  • 79. Tacrolimus in solid organ transplantation: an update.
    Shapiro R.
    Transplant Proc; 1999 Sep 27; 31(6):2203-5. PubMed ID: 10500545
    [No Abstract] [Full Text] [Related]

  • 80. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation.
    Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS.
    Transplantation; 1998 Jan 27; 65(2):180-7. PubMed ID: 9458011
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.